Department of Urology, Columbia University, 161 Fort Washington Avenue, 11th Floor, New York, NY 10032, USA.
World J Urol. 2010 Oct;28(5):565-70. doi: 10.1007/s00345-010-0552-4. Epub 2010 Apr 23.
Changes in the management of minimally invasive oncologic renal surgery have introduced ablative therapies as the most recent advancement in minimally invasive technology.
The current evidence-based medicine on the topic of laparoscopic (LCA) and percutaneous (PCA) renal cryoablation was gathered and outlined in this review. The mechanism and surgical approach to performing renal cryoablation as well a focus on the oncologic and renal functional outcomes after cryoablation will be discussed.
Although initially recommended only for patients who were at a high surgical risk, presence of a solitary kidney, or in elderly patients, renal cryoablation, has expanded to include the majority of patients being treated for a small (<3.5 cm) renal cortical neoplasm.
Renal cryoablation has become a viable minimally invasive treatment option for the majority patients diagnosed with a small (≤ 3cm) renal cortical neoplasm. Cryoablation does not seem to impact post-ablative renal function regardless of surgical approach, pre-ablation renal function, or presence of a solitary kidney.
微创肿瘤学肾脏手术治疗方法的变化带来了消融疗法，这是微创技术的最新进展。
本综述收集并概述了当前关于腹腔镜（LCA）和经皮（PCA）肾脏冷冻消融的循证医学证据。本文将讨论冷冻消融的作用机制和手术方法，以及关注冷冻消融后的肿瘤学和肾功能结果。
尽管最初仅推荐用于手术风险高、只有一个肾脏或老年患者，但冷冻消融已扩展到包括大多数接受小（<3.5cm）肾皮质肿瘤治疗的患者。
冷冻消融已成为大多数诊断为小（≤3cm）肾皮质肿瘤患者的可行微创治疗选择。无论手术方法、消融前肾功能或是否存在孤立肾，冷冻消融似乎都不会影响消融后的肾功能。
